Tarsus Pharmaceuticals, Inc. is making headlines yet again by announcing plans to acquire Alkeus Pharmaceuticals, Inc.—as well as its late-stage investigational therapy for Stargardt disease.
Headlines yet again, you say?
Indeed we do. Just last month, Tarsus shared its intention to acquire iRenix Medical along with its investigational ocular antiseptic for reducing post-procedural pain and corneal toxicity.
- Read up on those plans.
Fast forward to now: The company is expanding its presence in the retina space.
So what should we know about this new deal?
While the transaction is still pending, the company shared that both companies’ Board of Directors (plus Alkeus’ stockholders) have given the OK.
As for the monetary details: This includes upfront consideration of an estimated $450 million:
- $270 million in cash
- $180 million in Tarsus common stock
- To be issued to Alkeus stockholders at the acquisition’s closing
- The price: $61.38 per share
Anything else to know?
Oh yes … the proposed deal also includes future milestones and royalty payments for Alkeus’s—still investigational— Stargardt asset (which we’ll talk about in a moment).
- (Up to) $350 million upon the potential regulatory approval and first commercial sales
- Low single-digit tiered descending royalties as a percentage of net sales
Last question: When is this expected to close?
Tarsus only said that it’s expected to “close in 2026,” so sometime between now and the end of Q4.
And, of course, it’s subject to other customary closing conditions.
Duly noted. Now let’s talk about Alkeus—and this asset.
Founded in 2010 and operating out of Cambridge, Massachusetts, the privately-held, retinal disease-focused biotechnology company is developing therapies for inherited and degenerative retinal diseases.
- Its lead asset: gildeuretinol acetate (ALK-001)
What this is: A new molecular entity designed to reduce the dimerization of vitamin A without modulating the visual cycle.
To note: While it’s primary proposed indication is for Stargardt, it’s also under investigation for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Duly noted. So what’s the latest clinical update on ALK-001?
Just a couple months ago, Alkeus announced just the first patient dosing in its pivotal phase 3 NORTHSTAR trial (NCT07419334) for Stargardt.
- Check out details on the study’s setup and outcome measures.
And prior to this update: The candidate was granted four FDA designations for Stargardt, including Breakthrough Therapy, Rare Pediatric Disease, Fast Track, and Orphan Drug.
Impressive! Tell me more about its clinical evaluation progress.
ALK-001 has undergone investigation in four separate clinical trials as part of the Tolerability and Effects of ALK-001 on Stargardt diseasE (TEASE) program.
- See here for a look at each of these.
Also worth noting: It was evaluated in the phase 3 SAGA trial—though that was for its other proposed indication (GA). We covered those May 2025 results here.
- And see here for favorable safety data supporting its use for dry AMD.
Regarding this Stargardt indication—how has ALK-001 performed so far?
We’ll refer to data from the TEASE-1 and TEASE-3 studies.
- In TEASE-1: ALK-001 slowed the growth rate of atrophic retinal lesion area by 21.6% versus untreated patients—while also demonstrating a 29.5% reduction in the growth rate of atrophic lesions. More on this here.
- And in TEASE-3: Interim data found ALK-001 resulted in a 21% reduction in the growth rate of retinal atrophic lesions (p<0.001, square root units, 28% effect for untransformed areas) against untreated patients.
See here for its safety and tolerability performance. Also check out more on its functional and long-term data.
Nice! So, circling back to this ongoing phase 3 trial ...
Right! With patient dosing already underway, the expectation is for top-line data to be ready by the second half (H2) 2029.